ArticleFrontiers in pharmacology2026

Cost-effectiveness analysis of trastuzumab deruxtecan versus ramucirumab plus paclitaxel as second-line treatment for HER2-positive metastatic gastric cancer or gastroesophageal junction adenocarcinoma.

Yitian Lang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.